As hepatitis B research progresses, achieving higher functional cure rates is becoming more feasible. It is vital that ...

GlobalData expects the chronic hepatitis B therapeutics market across major markets to climb from $1.5 billion in 2024 to ...

A recent study published in Alimentary Pharmacology and Therapeutics reports that patients with a lower hepatitis B virus (HBV) haplotype number of less than or equal to two are more likely to achieve ...

Hepatitis B virus (HBV) is a significant public health problem, with over 296 million people chronically infected worldwide. Despite the availability of a safe and effective vaccine for over 40 years, ...

Despite untreated HBV being linked to earlier mortality, higher all-cause and liver-related death, and a 10% to 25% lifetime risk of developing hepatocellular carcinoma (HCC), only 29% of qualifying ...

There is a lack of data supporting the notion that antiviral treatments can benefit children with chronic hepatitis B (CHB) having high viremia and normal or mildly elevated serum alanine ...

Antiviral treatments play a crucial role in the survival of patients with either hepatitis B or C and liver cancer, but researchers have found that antiviral therapy is “severely underutilized” even ...

Geneva, March 30, 2023 – More than half of patients who suffer from chronic hepatitis B have the e antigen (HBeAg)-negative form of the disease. Even after many years of antiviral treatment with ...

Chronic hepatitis B occurs when the body cannot eliminate the hepatitis B virus following an acute infection. Having chronic (or lifelong) hepatitis B can increase a person’s risk of developing ...

As RFK Jr.'s new vaccine panel ponders changing the hepatitis B vaccination schedule, some doctors recall past patients, ...

Vaccine advisers to the US Centers for Disease Control and Prevention may vote this week to make a major change to the ...

The nation's top vaccine advisory panel is expected to debate on Thursday whether to delay the first dose of the hepatitis B ...